Search Results - "Soukiazian, Nyrie"

Risk stratification of ER‐positive breast cancer patients: A multi‐institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26 by Turner, Bradley M., Gimenez‐Sanders, Mary Ann, Soukiazian, Armen, Breaux, Andrea C., Skinner, Kristin, Shayne, Michelle, Soukiazian, Nyrie, Ling, Marilyn, Hicks, David G.

“…The skyrocketing cost of health‐care demands that we question when to use multigene assay testing in the planning of treatment for breast cancer patients. A…”
Get full text

Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score by Turner, Bradley M, Skinner, Kristin A, Tang, Ping, Jackson, Mary C, Soukiazian, Nyrie, Shayne, Michelle, Huston, Alissa, Ling, Marilyn, Hicks, David G

“…Oncotype DX (Genomic Health, Redwood City, CA, USA, current list price $4,350.00) is a multigene quantitative reverse transcription-polymerase chain…”
Get full text

Abstract P3-07-06: ER+ patients with an average modified Magee score ≤ 18 have a low likelihood of breast cancer recurrence and a high likelihood of an Oncotype Dx® recurrence score < 26 by Khatib, Hasan, Sanders, Mary Ann G, Breaux, Andrea, Soukiazian, Armen, Soukiazian, Nyrie, Hicks, David, Turner, Bradley M

“…Abstract INTRODUCTION: The recent TAILORx results suggest that adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with…”
Get full text